| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial
|
Henderson, Michael A
|
|
2015
|
16 |
9 |
p. 1049-1060
12 p.
|
artikel
|
| 2 |
Adjuvant radiation for patients with melanoma
|
Brady, Mary S
|
|
2015
|
16 |
9 |
p. 1003-1004
2 p.
|
artikel
|
| 3 |
A novel clinicogenetic prognostic score for follicular lymphoma
|
López-Guillermo, Armando
|
|
2015
|
16 |
9 |
p. 1011-1012
2 p.
|
artikel
|
| 4 |
Bevacizumab: no comeback in early breast cancer?
|
Bartsch, Rupert
|
|
2015
|
16 |
9 |
p. 1001-1003
3 p.
|
artikel
|
| 5 |
Cancer risk in the transgender community
|
The Lancet Oncology,
|
|
2015
|
16 |
9 |
p. 999-
1 p.
|
artikel
|
| 6 |
Cancer strategy to help NHS achieve world-class outcomes
|
Tanday, Sanjay
|
|
2015
|
16 |
9 |
p. e428-
1 p.
|
artikel
|
| 7 |
Clinical cancer genomic analysis: data engineering required
|
Doig, Kenneth
|
|
2015
|
16 |
9 |
p. 1015-1017
3 p.
|
artikel
|
| 8 |
Consensus on biomarkers for neuroendocrine tumour disease
|
Oberg, Kjell
|
|
2015
|
16 |
9 |
p. e435-e446
nvt p.
|
artikel
|
| 9 |
Consensus on the management of intracranial germ-cell tumours
|
Murray, Matthew J
|
|
2015
|
16 |
9 |
p. e470-e477
nvt p.
|
artikel
|
| 10 |
Correction to Lancet Oncol 2011; 12: 1051
|
|
|
2015
|
16 |
9 |
p. e427-
1 p.
|
artikel
|
| 11 |
Correction to Lancet Oncol 2015; 16: 1127
|
|
|
2015
|
16 |
9 |
p. e427-
1 p.
|
artikel
|
| 12 |
Correction to Lancet Oncol 2015; 16: 634, 637
|
|
|
2015
|
16 |
9 |
p. e427-
1 p.
|
artikel
|
| 13 |
Correction to Lancet Oncol 2015; 16: 388
|
|
|
2015
|
16 |
9 |
p. e427-
1 p.
|
artikel
|
| 14 |
Correction to Lancet Oncol 2015; 16: 967–78
|
|
|
2015
|
16 |
9 |
p. e427-
1 p.
|
artikel
|
| 15 |
Disparities in cancer mortality for elderly poor in the USA
|
Gruber, Karl
|
|
2015
|
16 |
9 |
p. e431-
1 p.
|
artikel
|
| 16 |
Docetaxel for hormone-sensitive metastatic prostate cancer
|
Baker, Holly
|
|
2015
|
16 |
9 |
p. e432-
1 p.
|
artikel
|
| 17 |
Edinburgh Festival Fringe Round Up
|
Murray, Andrew Hunter
|
|
2015
|
16 |
9 |
p. 1021-1022
2 p.
|
artikel
|
| 18 |
Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial
|
Moss, Sue M
|
|
2015
|
16 |
9 |
p. 1123-1132
10 p.
|
artikel
|
| 19 |
EMA paediatric medicine waivers
|
Burki, Talha Khan
|
|
2015
|
16 |
9 |
p. e429-
1 p.
|
artikel
|
| 20 |
Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies
|
|
|
2015
|
16 |
9 |
p. 1061-1070
10 p.
|
artikel
|
| 21 |
Epigenetic approaches to overcoming chemotherapy resistance
|
Strauss, Julius
|
|
2015
|
16 |
9 |
p. 1013-1015
3 p.
|
artikel
|
| 22 |
Faces of breast cancer: a personal approach
|
Lobo, Patricia
|
|
2015
|
16 |
9 |
p. 1024-
1 p.
|
artikel
|
| 23 |
Fewer than three doses of HPV vaccine
|
Lehtinen, Matti
|
|
2015
|
16 |
9 |
p. e422-e423
nvt p.
|
artikel
|
| 24 |
Fewer than three doses of HPV vaccine
|
Jit, Mark
|
|
2015
|
16 |
9 |
p. e423-e424
nvt p.
|
artikel
|
| 25 |
Fewer than three doses of HPV vaccine – Authors' reply
|
Kreimer, Aimée R
|
|
2015
|
16 |
9 |
p. e424-e425
nvt p.
|
artikel
|
| 26 |
Genetic mutations and outcome in myeloma
|
Bagcchi, Sanjeet
|
|
2015
|
16 |
9 |
p. e434-
1 p.
|
artikel
|
| 27 |
Genetic testing for patients with colorectal cancer
|
Burki, Talha Khan
|
|
2015
|
16 |
9 |
p. e430-
1 p.
|
artikel
|
| 28 |
Guadecitabine for AML and MDS: hype or hope?
|
Kharfan-Dabaja, Mohamed A
|
|
2015
|
16 |
9 |
p. 1009-1011
3 p.
|
artikel
|
| 29 |
High HLA-DP expression and graft-versus-host disease
|
Baker, Holly
|
|
2015
|
16 |
9 |
p. e434-
1 p.
|
artikel
|
| 30 |
Hypofractionated breast radiation reduces acute toxicities
|
Brower, Vicki
|
|
2015
|
16 |
9 |
p. e432-
1 p.
|
artikel
|
| 31 |
Ibrutinib promising in subtype of DLBCL
|
Brower, Vicki
|
|
2015
|
16 |
9 |
p. e428-
1 p.
|
artikel
|
| 32 |
Inherited cylindromas: lessons from a rare tumour
|
Rajan, Neil
|
|
2015
|
16 |
9 |
p. e460-e469
nvt p.
|
artikel
|
| 33 |
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
|
Pastore, Alessandro
|
|
2015
|
16 |
9 |
p. 1111-1122
12 p.
|
artikel
|
| 34 |
MRS for non-invasive medulloblastoma subgrouping
|
Bagcchi, Sanjeet
|
|
2015
|
16 |
9 |
p. e433-
1 p.
|
artikel
|
| 35 |
Neoadjuvant chemoradiation in oesophageal cancer
|
Mariette, Christophe
|
|
2015
|
16 |
9 |
p. 1008-1009
2 p.
|
artikel
|
| 36 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|
Shapiro, Joel
|
|
2015
|
16 |
9 |
p. 1090-1098
9 p.
|
artikel
|
| 37 |
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
|
Bear, Harry D
|
|
2015
|
16 |
9 |
p. 1037-1048
12 p.
|
artikel
|
| 38 |
NICE guidance on nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
|
Hall, Caroline J
|
|
2015
|
16 |
9 |
p. 1019-1020
2 p.
|
artikel
|
| 39 |
Nodal radiation in breast cancer does not improve survival
|
Brower, Vicki
|
|
2015
|
16 |
9 |
p. e430-
1 p.
|
artikel
|
| 40 |
Now and at the Hour of Our Death
|
Burki, Talha Khan
|
|
2015
|
16 |
9 |
p. 1023-
1 p.
|
artikel
|
| 41 |
Research funding under review in UK and USA
|
Burki, Talha Khan
|
|
2015
|
16 |
9 |
p. 1018-
1 p.
|
artikel
|
| 42 |
Role of rolapitant in chemotherapy-induced emesis
|
Olver, Ian
|
|
2015
|
16 |
9 |
p. 1006-1007
2 p.
|
artikel
|
| 43 |
SABR vs surgery for NSCLC in the media
|
Rice, David
|
|
2015
|
16 |
9 |
p. e422-
1 p.
|
artikel
|
| 44 |
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
|
Reid, Tony
|
|
2015
|
16 |
9 |
p. 1133-1142
10 p.
|
artikel
|
| 45 |
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
|
Rapoport, Bernardo L
|
|
2015
|
16 |
9 |
p. 1079-1089
11 p.
|
artikel
|
| 46 |
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
|
Schwartzberg, Lee S
|
|
2015
|
16 |
9 |
p. 1071-1078
8 p.
|
artikel
|
| 47 |
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
|
Issa, Jean-Pierre J
|
|
2015
|
16 |
9 |
p. 1099-1110
12 p.
|
artikel
|
| 48 |
T-cell receptor therapy shows promise in multiple myeloma
|
Bagcchi, Sanjeet
|
|
2015
|
16 |
9 |
p. e429-
1 p.
|
artikel
|
| 49 |
The Pill's gestation: from birth control to cancer prevention
|
Wentzensen, Nicolas
|
|
2015
|
16 |
9 |
p. 1004-1006
3 p.
|
artikel
|
| 50 |
The UK Age Trial: screening women in their forties
|
Kopans, Daniel B
|
|
2015
|
16 |
9 |
p. 1012-1013
2 p.
|
artikel
|
| 51 |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
|
Tan, Chee-Seng
|
|
2015
|
16 |
9 |
p. e447-e459
nvt p.
|
artikel
|
| 52 |
Trends in euthanasia and assisted suicide
|
Burki, Talha Khan
|
|
2015
|
16 |
9 |
p. e433-
1 p.
|
artikel
|
| 53 |
Urine test can detect early stage pancreatic cancer
|
Bagcchi, Sanjeet
|
|
2015
|
16 |
9 |
p. e431-
1 p.
|
artikel
|
| 54 |
Vosaroxin in acute myeloid leukaemia
|
Bornhäuser, Martin
|
|
2015
|
16 |
9 |
p. 1000-1001
2 p.
|
artikel
|
| 55 |
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
|
Ravandi, Farhad
|
|
2015
|
16 |
9 |
p. 1025-1036
12 p.
|
artikel
|
| 56 |
Will the revised class waiver list make it?
|
Vassal, Gilles
|
|
2015
|
16 |
9 |
p. e425-e426
nvt p.
|
artikel
|
Tijdschrift beschrijving